scholarly journals The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 933
Author(s):  
Carmine Izzo ◽  
Monica Annunziata ◽  
Giuseppe Melara ◽  
Roberta Sciorio ◽  
Marcello Dallio ◽  
...  
Keyword(s):  
Liver Disease ◽  
Therapeutic Effects ◽  
Alcoholic Fatty Liver ◽  
Liver Disorders ◽  
Liver Protection ◽  
New Treatment ◽  
Alcoholic Fatty Liver Disease

Many studies have shown that resveratrol has a lot of therapeutic effects on liver disorders. Its administration can significantly increase the survival rate after liver transplantation, reduce fat deposition and ischemia-induced necrosis and apoptosis in Wistar rats. Resveratrol can provide Liver protection against chemical, cholestatic, and alcohol-mediated damage. It can improve glucose metabolism and lipid profile, reduce liver fibrosis, and steatosis. Additionally, it is capable of altering the fatty acid composition of the liver cells. Resveratrol may be a potential treatment option for the management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant, and calorie-restricting effects. There are also studies that have evaluated the effect of resveratrol on lipid and liver enzyme profiles among patients with metabolic syndrome (MetS) and related disorders. Based on the extent of liver disease worldwide and the need to find new treatment possibilities, this review critically examines current in vitro and in vivo preclinical studies and human clinical studies related to liver protection.

scholarly journals Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease

2018 ◽  
Vol 24 (36) ◽  
pp. 4104-4118 ◽  
Author(s):  
Jorge-Luis Torres ◽  
Ignacio Novo-Veleiro ◽  
Laura Manzanedo ◽  
Lucía Alvela-Suárez ◽  
Ronald Macías ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Liver Disorders ◽  
Alcoholic Fatty Liver Disease

scholarly journals Naringin protects against non-alcoholic fatty liver disease by promoting autophagic flux and lipophagy

2021 ◽  
Author(s):  
Lingling Guan ◽  
Lan Guo ◽  
Heng Zhang ◽  
Hao Liu ◽  
Yuan Qiao ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Autophagic Flux ◽  
Mechanism Study ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Background and Purpose: The autophagic degradation of lipid droplets (LDs), termed lipophagy, is the main mechanism contributing to lipid consumption in hepatocytes. The identification of effective and safe natural compounds that target lipophagy to eliminate excess lipids may be a potential therapeutic strategy for non-alcoholic fatty liver disease (NAFLD). Here, we investigated the effects of naringin on NAFLD and the underlying mechanism. Experimental Approach: The role of naringin was investigated in mice fed a high-fat diet (HFD) to induce NAFLD, as well as in AML12 cells and primary hepatocytes stimulated by palmitate (PA). Transcription factor EB (TFEB)-knockdown AML12 cells and hepatocyte-specific TFEB-knockout mice were also used for the mechanism study. In vivo and in vitro studies were conducted using transmission electron microscopy, immunofluorescence techniques and western blot analysis. Key Results: We found that naringin treatment effectively relieved HFD-induced hepatic steatosis in mice and inhibited palmitate (PA)-induced lipid accumulation in hepatocytes. The increased p62 and LC3-II levels observed with excess lipid-support autophagosome accumulation and impaired autophagic flux. Treatment with naringin restored TFEB-mediated lysosomal biogenesis, thereby promoting the fusion of autophagosomes and lysosomes, restoring impaired autophagic flux and further inducing lipophagy. However, the knockdown of TFEB in hepatocytes or the hepatocyte-specific knockout of TFEB in mice abrogated naringin-induced lipophagy, which eliminated the therapeutic effect of naringin on hepatic steatosis. Conclusion and Implications: These results demonstrate that TFEB-mediated lysosomal biogenesis and subsequent lipophagy play essential roles in the ability of naringin to mitigate hepatic steatosis and suggest that naringin is a promising drug for treating or relieving NAFLD.

scholarly journals The role of the gut microbiome and exercise in non-alcoholic fatty liver disease

2020 ◽  
Vol 13 ◽  
pp. 175628482094174
Author(s):  
Veera Houttu ◽  
Ulrika Boulund ◽  
Aldo Grefhorst ◽  
Maarten R. Soeters ◽  
Sara-Joan Pinto-Sietsma ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Liver Disease ◽  
Fatty Liver ◽  
Gut Microbiome ◽  
Fatty Liver Disease ◽  
Inflammatory Responses ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

In recent years, the human gut microbiome has been found to influence a multitude of non-communicable diseases such as cardiovascular disease and metabolic syndrome, with its components type 2 diabetes mellitus and obesity. It is recognized to be mainly influenced by environmental factors, such as lifestyle, but also genetics may play a role. The interaction of gut microbiota and obesity has been widely studied, but in regard to non-alcoholic fatty liver disease (NAFLD) as a manifestation of obesity and insulin resistance, the causal role of the gut microbiome has not been fully established. The mechanisms by which the gut microbiome influences lipid accumulation, inflammatory responses, and occurrence of fibrosis in the liver are a topic of active research. In addition, the influence of exercise on gut microbiome composition is also being investigated. In clinical trials, exercise reduced hepatic steatosis independently of weight reduction. Other studies indicate that exercise may modulate the gut microbiome. This puts forward the question whether exercise could mediate its beneficial effects on NAFLD via changes in gut microbiome. Yet, the specific mechanisms underlying this potential connection are largely unknown. Thus, associative evidence from clinical trials, as well as mechanistic studies in vivo are called for to elucidate the relationship between exercise and the gut microbiome in NAFLD. Here, we review the current literature on exercise and the gut microbiome in NAFLD.

scholarly journals Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver diseaseviaIL-22-mediated JAK1/STAT3/BAX signaling

2018 ◽  
Vol 9 (12) ◽  
pp. 6298-6306 ◽  
Author(s):  
Juanjuan Zhu ◽  
Mingyu Zhou ◽  
Xueke Zhao ◽  
Mao Mu ◽  
Mingliang Cheng
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Blueberry, combined with probiotics, improves non-alcoholic fatty liver disease bothin vivoandin vitroby IL-22.

Sign in / Sign up

Export Citation Format

Share Document